Compound
← Compound
Official website →
NVONovo Nordisk A S
Quotes delayed by up to 15 minutes · informational, not investment advice
Escopo e origem dos dados
- Ativo
- NVO
- Moeda das demonstrações
- DKK
- Último período anual nesta tabela
- 2025-12-31
- Fonte das demonstrações
- SEC EDGAR
Data de demonstração não é horário de cotação. Dado ausente não é zero. A cobertura varia por ativo e fonte; confira o documento original antes de interpretar um número.
Fontes e metodologiaAbout the company
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and…
IndustryDrug Manufacturers - General
Smart calendar
Organizing upcoming events...
Key metrics
What the market pays
P/E
Price divided by trailing 12-month earnings
10.74×
P/B
Price divided by book value
5.63×
EV/EBITDA
Enterprise value divided by operating cash generation
7.78×
EV/Revenue
Enterprise value divided by revenue
4.09×
What the company earns
ROE
Return on shareholders’ equity
59.1%
ROA
Return on all assets
19.6%
Gross margin
What remains after product costs
80.6%
Operating margin
What remains after operating the business
43.1%
Net margin
How much of each revenue unit becomes profit
35.3%
What it owes
Debt / Equity
Debt for each unit of shareholders’ equity
0.63
Total debt
Sum of borrowings
DKK 140.13B
Cash
Cash available to cover it
DKK 44.48B
Current ratio
Short-term assets divided by short-term liabilities
0.87
Free cash flow
Cash left after investing
DKK 42.4B
Risk and growth
Beta
Moves more (>1) or less (<1) than the market
0.35
Revenue growth
Compared with the same period a year earlier
2.1%
Earnings growth
Compared with the same period a year earlier
-20.8%
Dividend yield
Trailing 12-month distributions divided by price
4.2%
Market data provider figures for the latest published period. Informational, not investment advice.
Financial statements(DKK)
Income statement
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Receita | 176.95B | 232.26B | 290.4B | 309.06B |
| Custo dos produtos | -28.45B | -35.77B | -44.52B | -58.79B |
| Lucro bruto | 148.51B | 196.5B | 245.88B | 250.28B |
| Pesquisa e desenvolvimento | -24.05B |
News about NVO
Investing.com · 1 hour ago
Novo Nordisk open to M&A to strengthen weight-loss drug pipeline, CEO says
InfoMoney · 13 hours ago
CagriSema supera Mounjaro em perda de peso, segundo estudo da Novo Nordisk
Yahoo Finance · 19 hours ago
Why Novo Nordisk Stock Just Crashed
Bloomberg Markets · 20 hours ago
Accenture Up on Partnership with Anthropic; Novo Nordisk Falls on Turnaround | Stock Movers
Investing Brasil · 21 hours ago
Por que as ações da Novo Nordisk estão caindo hoje?
Follow NVO and get agent analysis of what is moving the stock.
Open Compound